U.S. Residential REITs Stock News

NasdaqGS:ATLC 1 Year Share Price vs Fair Value Explore Atlanticus Holdings's Fair Values from the Community and select...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

NYSE:CCL 1 Year Share Price vs Fair Value Explore Carnival Corporation &'s Fair Values from the Community and select...

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...

Earlier this month, Quanta Services completed a US$1.5 billion multi-tranche senior notes offering with maturities spanning 2028, 2031, and 2035, intending to use the proceeds to repay existing borrowings under its commercial paper program and senior credit facility. By extending its debt maturity profile and locking in fixed interest rates, Quanta Services could see changes in its financial flexibility and interest expenses, influencing its future capital allocation decisions. We'll explore...

GRAIL, Inc. reported second quarter and six-month results for the period ended June 30, 2025, showing sales of US$34.38 million and US$63.51 million respectively, with net losses narrowing substantially from the prior year and impairment charges decreasing to US$28 million from a very large US$1.42 billion a year earlier. This sharp reduction in both net loss and impairment charges points to improved operational discipline and financial stability at the company. We'll explore how GRAIL's...

Earlier this past week, Kymera Therapeutics announced positive results from its first KT-621 clinical trial, which delivered strong efficacy and a placebo-like safety profile, alongside new collaborations with Gilead and Sanofi and disclosure of a cash reserve near US$1 billion by July's end. An important takeaway is that Kymera's strengthened pipeline through high-profile partnerships and a substantial cash runway may provide meaningful support for future research and development...

Viridian Therapeutics recently reported its second quarter and six-month earnings for 2025, revealing a wider net loss of US$100.74 million and US$187.65 million respectively, both larger than the losses reported a year earlier. Alongside these results, the company filed a new shelf registration to potentially offer 11,228,650 shares, which may reflect ongoing capital needs and could influence future dilution concerns. We'll examine how the combination of larger losses and the shelf...

Formula One Group reported its second quarter 2025 earnings on August 7, showing sales of US$1.20 billion and net income of US$382 million, both up sharply from a year earlier. This marks a very large year-over-year increase in net income, highlighting the impact of strong commercial partnerships and expanding media revenues. We'll explore how this significant boost in quarterly profits could influence analyst expectations about Formula One Group's earnings trajectory and risk profile. These...

Abbott Laboratories recently reported strong financial results, achieving 18% annual earnings per share growth over the past three years and a 5.9% rise in revenue, while insider ownership was valued at US$1.1 billion. This combination of robust performance and significant insider confidence underlines stability in the company's leadership and alignment with shareholder interests. We'll explore how Abbott's large insider ownership and earnings momentum may shape its investment narrative...

PENN Entertainment recently completed a repurchase of 6,920,104 shares for US$115.6 million, reported improved second-quarter financial results, issued new revenue guidance, launched the FanCenter feature on ESPN BET, and made changes to its Compliance Committee. An important insight is PENN's investments in digital product development and compliance, alongside capital returns, highlight a multifaceted approach to shareholder value and operational growth. We'll explore how PENN's new...

In recent days, Solaris Energy Infrastructure was highlighted in a widely read industry outlook alongside peers, drawing increased attention from investors following sector commentary focused on oil stockpiles and shifting capital spending priorities. The company’s inclusion as a promising trade idea has sparked renewed interest in its position within the energy sector, especially amid analyst debates on capital discipline and the demand outlook for energy infrastructure. We’ll explore how...

Earlier this month, Universal Technical Institute reported higher third-quarter and year-to-date earnings, updated its fiscal 2025 guidance upward, and announced leadership changes at its San Antonio campus to support its skilled trades expansion. The addition of advanced EV diagnostic tools at multiple campuses and recent insider share purchases reflect broad-based efforts to address evolving industry needs and suggest growing internal confidence in UTI’s direction. We'll now explore how...

APi Group recently reported strong results, highlighted by robust organic revenue and adjusted EBITDA growth in its core Safety Services segment, alongside upward full-year earnings estimate revisions and increased institutional interest. This momentum underscores the impact of heightened safety regulations and expanding recurring revenue on the company's market enthusiasm and operational performance. Next, we’ll examine how the positive shift in earnings outlook may influence APi Group’s...

Earlier this month, CoStar Group extended its legal battle by filing a copyright infringement lawsuit against Zillow, alleging unauthorized use and distribution of over 46,000 copyrighted images and seeking damages potentially exceeding US$1 billion. This development highlights ongoing competitive and legal tensions within the digital real estate marketplace, raising complex questions about intellectual property protection and industry relationships. We'll explore how investor concerns...

Root, Inc. recently reported second quarter 2025 results, announcing a net income of US$20.9 million, a turnaround from a net loss of US$7.8 million in the prior year, and improved earnings per share from both basic and diluted continuing operations. This marks the company's first return to profitability for both the quarter and year-to-date periods, reflecting a substantial shift in operating performance. We will examine how Root's return to profitability could influence its ongoing...

Sensient Technologies recently participated in Baird's Investor Day in St. Louis and held a special company call, both events taking place earlier this week. These activities have raised expectations among investors for potential new disclosures or updates that could signal meaningful shifts in the company's direction. We'll explore how Sensient's investor conference participation and special call may influence its outlook for natural colors and clean-label growth. We've found 19 US stocks...

Gibraltar Industries recently announced its second-quarter 2025 results, reporting increased sales of US$309.52 million but a decrease in net income to US$26 million compared to the previous year, along with updated full-year guidance projecting lower earnings per share for 2025. While sales growth continued, the company's forecast for reduced annual earnings per share compared to 2024 signals shifting profitability dynamics that may influence expectations for the rest of the year. We'll now...

In recent weeks, Vertex Pharmaceuticals reported strong second-quarter financial results with US$2.96 billion in revenue and announced its investigational pain therapy VX-993 did not meet the primary endpoint in a Phase 2 trial, resulting in the decision not to pursue it further as a monotherapy for acute pain. This combination of a pipeline setback and robust financial performance, alongside continued share repurchases and confirmation of annual revenue guidance, reflects both the strengths...

Supernus Pharmaceuticals recently reported its second-quarter 2025 earnings, showing year-over-year revenue of US$165.45 million and net income of US$22.5 million, alongside updated full-year guidance reflecting anticipated revenue of US$670 million to US$700 million due to strong first-half results and the Sage acquisition. While quarterly revenue declined slightly from the prior year, improved profitability and the upward revision in annual guidance highlight a significant shift in...

Arcellx, Inc. recently reported its second quarter 2025 earnings, disclosing a net loss of US$52.77 million, up from US$27.2 million in the same period last year, and a basic loss per share of US$0.94 versus US$0.51 year-over-year. This sharp increase in net loss highlights considerable changes in the company's cost structure or spending priorities compared to previous periods. We'll examine how Arcellx's significantly higher net losses this quarter influence its investment narrative and...

ZoomInfo Technologies recently reported improved second quarter results with US$306.7 million in sales, returning to profitability and raising full-year revenue guidance to a range of US$1.215–1.225 billion, up from prior expectations. Along with completing a major share repurchase and appointing Michael Graham O’Brien as Chief Financial Officer, these developments highlight management’s confidence and a focus on operational discipline. We'll explore how the upgraded revenue outlook and...